MOMETASONE
(Elocom, Nasonex)Standard Prescription
mometasone nasal spray:__sprays in each nostril__(frequency)
mometasone lotion: apply drops to___(affected areas) ___ (frequency)
mometasone cream/ointment: apply thin film to__(affected areas)__(frequency)
mometasone lotion: apply drops to___(affected areas) ___ (frequency)
mometasone cream/ointment: apply thin film to__(affected areas)__(frequency)
Dosages
Nasal Spray
Allergic rhinitis
2-11 yrs: 1 spray into each nostril once daily
Nasal obstruction/adenoidal hypertrophy
Cream/Ointment
>2 yrs: Apply a thin film to affected areas once daily.
Lotion:
>12 yrs: Apply a few drops to affected areas once daily. Massage lightly into skin.
Allergic rhinitis
2-11 yrs: 1 spray into each nostril once daily
>12 yrs: 2 sprays into each nostril once daily
3-15 yrs: 1 spray into each nostril once daily x 6 weeks, then daily for the first 2 weeks of each month
>2 yrs: Apply a thin film to affected areas once daily.
Lotion:
>12 yrs: Apply a few drops to affected areas once daily. Massage lightly into skin.
Mechanism of Action
Corticosteroid
Forms Supplied
Nasal Spray: 50 mcg/spray, 140 doses per container
Cream/Ointment: 0.1% (15 g, 50 g)
Lotion: 0.1% (30 mL)
Cream/Ointment: 0.1% (15 g, 50 g)
Lotion: 0.1% (30 mL)
Comments
Nasal Spray
Avoid using higher than recommended dosages; suppression of linear growth (ie, reduction of growth velocity), reduced bone mineral density, or hypercortisolism (Cushing syndrome) may occur; titrate to lowest effective dose. Reduction in growth velocity may occur when corticosteroids are administered to pediatric patients, even at recommended doses via intranasal route (monitor growth).
Cream/Ointment/Lotion
Do not use occlusive dressings.
Do not use in pediatric patients for longer than 3 weeks.
Discontinue therapy when control is achieved; reassess diagnosis if no improvement seen in 2 weeks.
Due to a higher BSA to weight ratio, pediatric patients are at a greater risk of HPA axis suppression and Cushing syndrome compared to adults. Application of topical steroids over >20% of BSA in pediatric patients increases risk of HPA axis suppression.
Avoid using higher than recommended dosages; suppression of linear growth (ie, reduction of growth velocity), reduced bone mineral density, or hypercortisolism (Cushing syndrome) may occur; titrate to lowest effective dose. Reduction in growth velocity may occur when corticosteroids are administered to pediatric patients, even at recommended doses via intranasal route (monitor growth).
Cream/Ointment/Lotion
Do not use occlusive dressings.
Do not use in pediatric patients for longer than 3 weeks.
Discontinue therapy when control is achieved; reassess diagnosis if no improvement seen in 2 weeks.
Due to a higher BSA to weight ratio, pediatric patients are at a greater risk of HPA axis suppression and Cushing syndrome compared to adults. Application of topical steroids over >20% of BSA in pediatric patients increases risk of HPA axis suppression.
References
44, 415, 416, 498
Last Edited
2022-07-06 23:37:36